HBM BioCapital with a committed capital of $ 170 million is a Cayman Islands limited partnership investing in private companies in the emerging pharma, biotechnology, medical devices and diagnostics industries. HBM BioCapital usually invests between $5 million to $10 million. Larger transactions are shared with HBM BioVentures. Investors in HBM BioCapital are HBM BioVentures, larger institutional investors and pharma entrepreneurs.
| Company | Date | Round | Size | Participants |
| Delenex Therapeutics | 5/11 | Series A | $19.3M | 6 |
| Delenex Therapeutics | 11/10 | Series A | $14M | 4 |
| MTM Laboratories | 10/09 | Series C | €39M | 5 |
| ESBATech | 8/08 | Series B | $22M | 7 |
| ESBATech | 8/06 | Series B | $41M | 7 |
